1. In Vivo
  2. >>Archive

Total Ankle Replacement Sparks New Race

Orthopedic companies now target the so-called extremities as an area of capable of producing double-digit growth in sales. To be sure, the markets are considerably smaller than hips or knees, but multinational leaders can’t ignore untapped potential when their core markets are stagnant, and a new front is forming in the battle for foot and ankle supremacy around an old but still underutilized device – total ankle replacement implants.

Orthopedic companies are being forced to search far and wide for markets with true growth potential. Established orthopedics companies Stryker Corp. and Smith & Nephew PLC have set up businesses in emerging market countries including China, India, and Brazil and in some cases have bolstered their presence through the acquisition of domestic companies. Even Medtronic PLC, which sells only spine devices in the US and Europe, jumped into China’s orthopedics industry with the acquisition of China Kanghui Holdings in 2012. [See Deal] (SeeAlso see "Could Medtronic’s Kanghui Purchase Set Course For US Entry?" - In Vivo, 22 October, 2012..)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Merck’s Digital Biomarker Strategy For Commercial Gains In Neurology

 
• By Jo Shorthouse

The integration of digital health tools into clinical research and patient care is gaining momentum, and Merck KGaA, Darmstadt, Germany is not letting the grass grow under its feet. With an approach to digital biomarkers, the company is seeking to redefine how neurological diseases are monitored and managed.

Rising Leaders 2025: Gunnar Sachs On Pursuing The Legal Path To Life Science Business Growth

 
• By Ashley Yeo

Not everyone welcomes change as much as lawyers do. There is much of that ahead for Clifford Chance partner and life science expert Gunnar Sachs as he negotiates political shifts and surfs the rising tide of legal challenges to help companies stay compliant and competitive. Musicianship provides the work-life balance.

Podcast: iOnctura’s Mission To Treat Rare Cancers With Precision Therapies

 
• By Jo Shorthouse

In Vivo spoke with Catherine Pickering, the CEO and founder of iOnctura, a UK-based clinical stage biotech company developing therapies for uveal melanoma and other hard-to-treat cancers by disrupting the tumor-stroma-immune interface.